These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 18262501

  • 21. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
    Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ, Ambs S.
    J Natl Cancer Inst; 2006 Jul 05; 98(13):911-9. PubMed ID: 16818855
    [Abstract] [Full Text] [Related]

  • 22. Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.
    Ohnstad HO, Castro R, Sun J, Heintz KM, Vassilev LT, Bjerkehagen B, Kresse SH, Meza-Zepeda LA, Myklebost O.
    Cancer; 2013 Mar 01; 119(5):1013-22. PubMed ID: 23165797
    [Abstract] [Full Text] [Related]

  • 23. Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer.
    Hitzenbichler F, Stoehr CG, Rogenhofer M, Wieland WF, Ruemmele P, Hartmann A, Stoehr R.
    Pathobiology; 2014 Mar 01; 81(2):53-9. PubMed ID: 24217660
    [Abstract] [Full Text] [Related]

  • 24. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes.
    McGraw KL, Cluzeau T, Sallman DA, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Solé F, Maciejewski J, List AF.
    Oncotarget; 2015 Oct 27; 6(33):34437-45. PubMed ID: 26416416
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
    Ponti F, Corsini S, Gnoli M, Pedrini E, Mordenti M, Sangiorgi L.
    Fam Cancer; 2016 Oct 27; 15(4):635-43. PubMed ID: 26956143
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer.
    Sanchez-Carbayo M, Socci ND, Kirchoff T, Erill N, Offit K, Bochner BH, Cordon-Cardo C.
    Clin Cancer Res; 2007 Jun 01; 13(11):3215-20. PubMed ID: 17545525
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium.
    Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FB, Tollenaar RA, Johnson N, Fletcher O, Peto J, Tommiska J, Blomqvist C, Nevanlinna HA, Healey CS, Dunning AM, Pharoah PD, Easton DF, Dörk T, Van't Veer LJ, Breast Cancer Association Consortium.
    Cancer Res; 2007 Oct 01; 67(19):9584-90. PubMed ID: 17909070
    [Abstract] [Full Text] [Related]

  • 31. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
    Akkiz H, Sümbül AT, Bayram S, Bekar A, Akgöllü E.
    Cancer Epidemiol; 2010 Aug 01; 34(4):448-52. PubMed ID: 20447891
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer.
    Zhang X, Pageon L, Post SM.
    Oncogene; 2015 Aug 13; 34(33):4412-20. PubMed ID: 25435368
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Distribution and Effects of CDKN2 p16 540 C>G and 580 C>T, and MDM2 SNP309 T>G Polymorphisms in Patients with Primary Brain Tumors.
    Kafadar A, Küçükhüseyin Ö, Turan S, Yenilmez EN, Tunoglu S, Zeybek U, Kaynar MY, Kemerdere R, Yaylim I.
    Anticancer Res; 2015 Jul 13; 35(7):3933-42. PubMed ID: 26124340
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.